SAB Biotherapeutics, Inc. SABS
3.29
(0.06)
(1.79%)
as of 25 Sep
- Market cap
- $304.8M
- P/E
- 0.0×
Follow SABS
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (19.21%) | (7.57%) | 4.80% | (21.16%) |
+8 more TTM periods Free account |
|
| (16.24%) | (6.57%) | 3.93% | (18.01%) | ||
ROIC |
(38.97%) | (29.58%) | (52.73%) | (47.07%) | |
Return on Tangible Assets |
(19.72%) | (8.06%) | 4.11% | (18.48%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.72) | (0.99) | (2.37) | (3.53) | |
Free Cash Flow |
(57.44) | (53.16) | (45.71) | (37.59) | |
Capital Expenditures |
(3.50) | (1.91) | (0.93) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(16.83%) | (15.17%) | (17.82%) | (13.45%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.48 | 5.45 | (10.51) | 1.76 | |
Depreciation/Fixed assets |
0.21 | 0.22 | 0.22 | 0.23 | |
Capex/Depreciation |
(1.16) | (0.64) | (0.31) | (0.02) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.68) | (0.96) | (2.32) | (3.52) | |
Capex per Share |
(0.04) | (0.04) | (0.05) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates